SFE Investment Counsel Has $5.71 Million Position in Becton Dickinson and Co (BDX)

SFE Investment Counsel lessened its holdings in Becton Dickinson and Co (NYSE:BDX) by 2.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 26,658 shares of the medical instruments supplier’s stock after selling 747 shares during the quarter. Becton Dickinson and accounts for 2.3% of SFE Investment Counsel’s investment portfolio, making the stock its 13th largest holding. SFE Investment Counsel’s holdings in Becton Dickinson and were worth $5,706,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Westwood Holdings Group Inc. increased its position in shares of Becton Dickinson and by 24.2% in the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after acquiring an additional 205,721 shares during the period. Colony Group LLC increased its position in shares of Becton Dickinson and by 2.1% in the second quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after acquiring an additional 239 shares during the period. State Street Corp increased its position in shares of Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares during the period. Peapack Gladstone Financial Corp increased its position in shares of Becton Dickinson and by 1.3% in the second quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after acquiring an additional 453 shares during the period. Finally, Zions Bancorporation increased its position in shares of Becton Dickinson and by 23.7% in the third quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after acquiring an additional 2,050 shares during the period. Institutional investors own 75.68% of the company’s stock.

Get Becton Dickinson and alerts:

BDX has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the company a “buy” rating in a research report on Friday, December 29th. Argus boosted their price objective on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Bank of America restated a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research report on Friday, January 19th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $237.27.

Shares of Becton Dickinson and Co (NYSE BDX) opened at $217.14 on Friday. The firm has a market cap of $51,160.00, a PE ratio of 165.76, a PEG ratio of 1.45 and a beta of 1.12. The company has a debt-to-equity ratio of 1.04, a quick ratio of 5.03 and a current ratio of 1.54. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.33 EPS. sell-side analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is 229.01%.

TRADEMARK VIOLATION WARNING: “SFE Investment Counsel Has $5.71 Million Position in Becton Dickinson and Co (BDX)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/sfe-investment-counsel-has-5-71-million-position-in-becton-dickinson-and-co-bdx/1857219.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).